Journal article
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
F Ravandi, GJ Roboz, AH Wei, H Döhner, C Pocock, D Selleslag, P Montesinos, H Sayar, M Musso, A Figuera-Alvarez, H Safah, W Tse, SK Sohn, D Hiwase, T Chevassut, F Pierdomenico, I La Torre, B Skikne, R Bailey, J Zhong Show all
Journal of Hematology and Oncology | BMC | Published : 2021
Abstract
Background: Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P < 0.001) and relapse-free survival by 5.3 months (P < 0.001) compared with placebo in patients with AML in first remission after IC who were not candidates for transplant. Currently, the QUAZAR AML-001 trial provides the most comprehensive safety information associated with oral azacitidine maintenance therapy. Reviewed here are common adverse events (AEs) during oral aza..
View full abstractGrants
Funding Acknowledgements
This study was sponsored and funded by Celgene, a Bristol-Myers Squibb Company.